Related references
Note: Only part of the references are listed.Analysis of responder-based endpoints: improving power through utilising continuous components
James Wason et al.
TRIALS (2020)
B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan The PARADIGM-HF Trial
Peder Langeland Myhre et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Prognostic value of NT-proBNP added to clinical parameters to predict two-year prognosis of chronic heart failure patients with mid-range and reduced ejection fraction - A report from FAR NHL prospective registry
Jindrich Spinar et al.
PLOS ONE (2019)
Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF study
Paul Welsh et al.
EUROPEAN JOURNAL OF HEART FAILURE (2018)
Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective internationalmulti-ethnic cohort study
Carolyn S. P. Lam et al.
EUROPEAN HEART JOURNAL (2018)
Associations With and Prognostic and Discriminatory Role of N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Versus Mid-range Versus Reduced Ejection Fraction
Gianluigi Savarese et al.
JOURNAL OF CARDIAC FAILURE (2018)
Natriuretic Peptides as Biomarkers of Treatment Response in Clinical Trials of Heart Failure
Muthiah Vaduganathan et al.
JACC-HEART FAILURE (2018)
Reassessing the Role of Surrogate End Points in Drug Development for Heart Failure
Stephen J. Greene et al.
CIRCULATION (2018)
Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study
Burkert Pieske et al.
EUROPEAN HEART JOURNAL (2017)
Stan: A Probabilistic Programming Language
Bob Carpenter et al.
JOURNAL OF STATISTICAL SOFTWARE (2017)
Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction
Inder S. Anand et al.
JACC-HEART FAILURE (2017)
N-terminal pro-brain natriuretic peptide and cardiovascular or all-cause mortality in the general population: A meta-analysis
Zhaohua Geng et al.
SCIENTIFIC REPORTS (2017)
Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation
Soren Lund Kristensen et al.
CIRCULATION-HEART FAILURE (2017)
The Association of Five-Year Changes in the Levels of N-Terminal Fragment of the Prohormone Brain-Type Natriuretic Peptide (NT-proBNP) with Subsequent Heart Failure and Death in Patients with Stable Coronary Artery Disease: The Heart and Soul Study
Rakesh K. Mishra et al.
CARDIOLOGY (2017)
Usefulness of Serial N-terminal Pro-B-type Natriuretic Peptide Measurements to Predict Cardiac Death in Acute and Chronic Dilated Cardiomyopathy in Children
Susanna L. den Boer et al.
AMERICAN JOURNAL OF CARDIOLOGY (2016)
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Piotr Ponikowski et al.
EUROPEAN HEART JOURNAL (2016)
Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure
Michael R. Zile et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)
Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure
John J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Clinical profile and prognostic significance of natriuretic peptide trajectory following hospitalization for worsening chronic heart failure: findings from the ASTRONAUT trial
Stephen J. Greene et al.
EUROPEAN JOURNAL OF HEART FAILURE (2015)
Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction The SOCRATES-REDUCED Randomized Trial
Mihai Gheorghiade et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
A systematic review of BNP and NT-proBNP in the management of heart failure: overview and methods
Mark Oremus et al.
HEART FAILURE REVIEWS (2014)
Spironolactone for Heart Failure with Preserved Ejection Fraction
Bertram Pitt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure
John J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Clyde W. Yancy et al.
CIRCULATION (2013)
Effect of Spironolactone on Diastolic Function and Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction The Aldo-DHF Randomized Controlled Trial
Frank Edelmann et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
B-Type Natriuretic Peptide and Prognosis in Heart Failure Patients With Preserved and Reduced Ejection Fraction
Dirk J. van Veldhuisen et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Comparisons of Analysis Methods for Proof-of-Concept Trials
K. E. Karlsson et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2013)
Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP-CHF study
John G. F. Cleland et al.
EUROPEAN JOURNAL OF HEART FAILURE (2012)
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial
Scott D. Solomon et al.
LANCET (2012)
Obesity paradox and risk of sudden death in heart failure: Results from the MUerte Subita en Insuficiencia Cardiaca (MUSIC) Study
Paloma Gastelurrutia et al.
AMERICAN HEART JOURNAL (2011)
Prognostic Value of Baseline Plasma Amino-Terminal Pro-Brain Natriuretic Peptide and Its Interactions With Irbesartan Treatment Effects in Patients With Heart Failure and Preserved Ejection Fraction Findings From the I-PRESERVE Trial
Inder S. Anand et al.
CIRCULATION-HEART FAILURE (2011)
NT-proBNP Provides Incremental Prognostic Information in Cardiac Outpatients With and Without Echocardiographic Findings
Stefan Toggweiler et al.
CLINICAL CARDIOLOGY (2011)
Is there an additional benefit of serial NT-proBNP measurements in patients with stable chronic heart failure receiving individually optimized therapy?
Jennifer Franke et al.
CLINICAL RESEARCH IN CARDIOLOGY (2011)
N-terminal pro-B-type natriuretic peptide is associated with sudden cardiac death risk: the Cardiovascular Health Study
Kristen K. Patton et al.
HEART RHYTHM (2011)
Association of Copeptin and N-Terminal proBNP Concentrations With Risk of Cardiovascular Death in Older Patients With Symptoms of Heart Failure
Urban Alehagen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Dynamic Cardiovascular Risk Assessment in Elderly People The Role of Repeated N-Terminal Pro-B-Type Natriuretic Peptide Testing
Christopher R. deFilippi et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
The prognostic value of repeated measurement of N-terminal pro-B-type natriuretic peptide in patients with chronic heart failure due to left ventricular systolic dysfunction
Milos Kubanek et al.
EUROPEAN JOURNAL OF HEART FAILURE (2009)
Relation of N-terminal pro-brain natriuretic peptide levels and their prognostic power in chronic stable heart failure to obesity status
Lutz Frankenstein et al.
EUROPEAN HEART JOURNAL (2008)
Plasma brain natriuretic peptide concentrations and the risk of cardiovascular events and death in general practice
Keizo Tsuchida et al.
JOURNAL OF CARDIOLOGY (2008)
Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial)
Serge Masson et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a β-blocker:: Results from the Carvedilol Or Metoprolol European Trial (COMET) trial
Lars G. Olsson et al.
EUROPEAN JOURNAL OF HEART FAILURE (2007)
Baseline and serial Neurohormones in patients with congestive heart failure treated with and without bucindolol: Results of the neurohumoral substudy of the beta-blocker evaluation of survival study (BEST)
Robert P. Frantz et al.
JOURNAL OF CARDIAC FAILURE (2007)
Head to head comparison of N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in patients with/without left ventricular systolic dysfunction
M. Vanderheyden et al.
CLINICAL BIOCHEMISTRY (2006)
Analytical relationships among biosite, bayer, and Roche methods for BNP and NT-proBNP - A preliminary study
E Sykes et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2005)
Use of NT-proBNP in routine testing and comparison to BNP
R Pfister et al.
EUROPEAN JOURNAL OF HEART FAILURE (2004)
NT-proBNP in severe chronic heart failure: rationale, design and preliminary results of the COPERNICUS NT-proBNP substudy
F Hartmann et al.
EUROPEAN JOURNAL OF HEART FAILURE (2004)
Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay
KTJ Yeo et al.
CLINICA CHIMICA ACTA (2003)
Effect of carvedilol on the morbidity of patients with severe chronic heart failure - Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study
M Packer et al.
CIRCULATION (2002)
Share Paper
